The crowd of walkers was sparse and well-spaced on the boardwalk at West Haven's Savin Rock shore on Thursday, March 26, 2020. The boardwalk is now closed.

The crowd of walkers was sparse and well-spaced on the boardwalk at West Haven's Savin Rock shore on Thursday, March 26, 2020. The boardwalk is now closed.

Photo: Mark Zaretsky / Hearst Connecticut Media /

The crowd of walkers was sparse and well-spaced on the boardwalk at West Haven's Savin Rock shore on Thursday, March 26, 2020. The boardwalk is now closed.

The crowd of walkers was sparse and well-spaced on the boardwalk at West Haven's Savin Rock shore on Thursday, March 26, 2020. The boardwalk is now closed.

Coronavirus Q&A: Well-controlled diabetes and coronavirus risk

Since the start of the COVID-19 crisis, medical and health questions have flooded in from readers.

Where is it safe to go, and how does the virus spread? Who is at higher risk? How do I keep myself and my family safe?

From day one, our reporters began looking for answers.

Two weeks ago, we brought you a round of answers to your medical questions.

This week, we went back to one of the experts who previously helped us: Dr. Dennis Brown, who heads Quinnipiac Universitys physician assistant program. Brown specializes in emergency management and community health.

Although the busy professor did not have time to sit down for a video interview early this week, he answered some questions via email.

Many of the questions came directly from readers, while reporters came up with some of their own inquiries based on what they had learned in the field.

Heres what Brown had to say.

Question: Is it unsafe for people with COVID-19 to take ibuprofen?

Answer: When it comes to using ibuprofen when you have COVID-19, medical recommendations vary, according to Brown.

Because the drug works by decreasing the bodys inflammatory response and that response is part of the immune systems reaction to try to kill the virus, some have expressed concern that the virus could do more harm in patients taking ibuprofen, Brown said.

To be safe, the professor recommended using acetaminophen (Tylenol) to ease fever and pains.

Q: Can multiple patients use the same respirator? If so, are there drawbacks?

A: Ventilators are designed to serve one person at a time, according to Brown.

While they can be adjusted to serve more than one patient, that measure is only taken in serious emergencies, when there are no other ventilators are available, Brown said.

There are drawbacks, especially as the best ventilator settings for each patient varies, he continued.

Q: How long after recovery from coronavirus would a test be able find a trace in your system?

A: Most recent data is suggesting that people are still shedding the virus up to three to five days after a severe illness, Brown said.

Q: Is there free testing available? Where?

A: For information on testing, Brown directed readers to use their local hospital COVID-19 hotlines, Connecticuts information hotline (211) or the state Department of Public Healths coronavirus FAQs, which are updated regularly and include a section on testing.

Q: If youre not leaving the house at all, is it still necessary to disinfect all surfaces inside daily?

A: While a full disinfection is probably not necessary, keeping the house clean is a great way to get rid of other bacteria and viruses that are still around, and to prevent illnesses such as the common cold, according to Brown.

Q: Will Connecticut hospitals accept home sewn face masks made of cotton pillowcase or T-shirt material?

A: Most hospitals are accepting homemade face masks, Brown said, adding that donors should check with the health-care facility beforehand as it may request specific patterns.

Q: Should blood donors be tested for COVID-19?

A: If the donor does not show symptoms, they will not be tested at this time, Brown said.

Anyone who has been exposed to COVID-19 should self-isolate for two weeks, according to Brown. Blood donors should then inform the Red Cross about any possible exposure when they give blood, he said.

Q: Are people with well-controlled diabetes still at very high risk for severe COVID-19?

A: Diabetics are more susceptible to having more severe infections because of a decrease in their immune systems response, Brown said.

Even someone whose diabetes is well controlled will not react to stress or illness in the same way as someone who does not suffer from the disease, according to Brown.

Q: My son has henoch schonlein purpura. Does this make COVID-19 more serious for him?

A: Brown could not find any literature on the topic, he said.

Given how many unknowns there are surrounding the virus, he recommended that the reader contact their pediatrician or hematologist.

meghan.friedmann@hearstmediact.com

Read more from the original source:
Coronavirus Q&A: Well-controlled diabetes and coronavirus risk - New Haven Register

A man with type 2 diabetes has described his COVID-19 experience, saying although it was scary, it is possible to beat.

The dad-of-two, who wished to remain anonymous during his interview with Teesside News Live newspaper, said: I didnt leave my bedroom for three weeks. I was listening to the news and I knew how serious it was. I would go to the bathroom but made sure it was disinfected before going back to bed.

His wife left meals for him outside his room and she slept in a makeshift bed in the lounge.

Initially the 46-year-old thought he had developed a chest infection after experiencing shortness of breath and a high temperature. It will not until his doctor suggested he go to hospital in mid-March that he learned he had become infected with coronavirus after he was tested.

The wagon driver from Billingham described his experience of COVID-19: They stuck a big swab down the back of my nose and throat which was quite painful and uncomfortable. I went home to bed and the next day I got a call from Public Health England to say the test was positive. I was shocked to hear that I thought it was just a chest infection.

He said his symptoms were very much up and down but his condition got significantly worse at night.

He said: I was getting really breathless and I couldnt sleep. I would close my eyes to go to sleep but I would get really short of breath and would worry in case I was going to stop breathing. It was a very scary feeling as I had no control over it at all.

Three weeks later he is feeling a lot better and has even been able to go out into the garden for some fresh air, but he still gets breathless walking around and has to take things easy.

He added: Dont get me wrong, I feel like Ive been one of the lucky ones. At the time I was diagnosed there were only a handful of cases round here. The spread of it has been rapid but I want people to know that is possible to beat.

Its been a very scary experience and I think it could take a few more weeks for me to be back to normal but Im glad to say Im getting back to some sort of normality.

In order to protect yourself from the virus, everyone should stay home as much as possible. For more information, and the official guidelines, please refer to the Government website.

Here is the original post:
Man with T2D recalls 'scary' COVID-19 experience but fully recovers - Diabetes.co.uk

As the number of UK cases of coronavirus continues to rise, what has become clear is how many of the patients to die from the virus have underlying health conditions that make them susceptible to catching it.

The death toll in Britain has exceeded 8,000. Most of thosewho have diedhave suffered fromunderlying health conditions.

Its a new infection, but from our experience with dealing with flu epidemics, we know that people with various conditions will fare worse, says Fan Chung, a professor of respiratory medicine at Imperial College. A paper has just published in the New England Journal of Medicine, that looked at the first 1,001 cases in Wuhan. The figures showed those with diabetes, high blood pressure, heart disease, COPD, cancer and renal disease, fared worse. And I suspect the people who very unfortunately died in the UK had one or any of those conditions."

A Chinese study hasfound people with heart disease, diabetes and cancer had a 79 per cent chance of being admitted to intensive care or dying from the virus, due to their weakened immune systems.

Here are the underlying health conditions that put you at higher risk of getting the coronavirus, anda reminder of how it might initially spread.

People with diabetes face a higher risk of complications if they get the coronavirus, due to the fact their fluctuating or elevated glucose levels leave them with lowered immunity. This also means they have less protection against getting the virus. Coronavirus or COVID-19 can cause more severe symptoms and complications in people with diabetes, says Dan Howarth from Diabetes UK. If you have diabetes and you have symptoms such as a cough, high temperature and feeling short of breath you need to monitor your blood sugar closely and call the NHS 111 phone service.

People with diabetes who dont experience symptoms and have recently travelled to any of the affected areas need to follow information on the NHS and theGOV.UKwebsites, adds Howarth. "These are updated regularly and are the most up-to-date source of information available.

Somebody with a heart condition is more likely to have a compromised immune system, so their immune response wont be as strong if exposed to a virus. COVID-19 also targets the lungs, which could cause problems for a diseased heart that has to work harder to get oxygenated blood around the body.

Asthma is a respiratory condition that leads to inflammation of the breathing tubes that transport air to and from the lungs.Coronavirus can cause respiratory problems for anyone, but for the 5.4million people in the UK with asthma, the risk is greater, says Jessica Kirby, Head of Health Advice at Asthma UK. Respiratory viruses like thiscan triggerasthma symptoms and couldlead to anasthma attack.

Kirby says if youre a sufferer, itsessential to takeyour preventer, daily as prescribed. This helps cut the risk of an asthma attack being triggered by any virus, including coronavirus, she says. Keeping a reliever inhaler to handis vital, soyoucan use it ifyou get asthmasymptoms.

Ifyourasthma symptomsgetworse, and you havent travelled to an at-risk area or been in contact with someone who has, make an appointment to see your GP as soon as you can. If you think you might have coronavirus, use the NHS 111 online coronavirus service."

COPD is the name for certain lung conditions that cause breathing difficulties, including emphysema, which is characterised by damage to the air sacs in the lungs,and chronic bronchitis, which is a long-term condition involving inflammation of the lungs airways. People with COPD are more likely to get coronavirus if exposed to the virus because they have damage to their epithelial lining, which makes it easier for viruses to enter the body.

Cancer patients are more susceptible due to their compromised immune system. Various cancer drugs and treatments, like chemotherapy, mean your immune system may be suppressed, says Prof Chung, and this would increase your chances of catching it. And if you do get it while you havecancer, you would probably fare worse than somebody with the virus who didnt have cancer.

Not a health condition as such, but many of the thousands of deaths so far have involved elderly people with underlying health conditions. The elderly are at greater risk, and government advice for the elderly to avoid crowded areas is sound advice, says Prof Chung. The figures we have so far seem to imply the risk increases above the age of 70. However its even worse for those over 80. The chances of getting it and faring worse increase two or three times above the age the 70, but even more so above 80.

In terms of children, who appear to be less prone to getting the coronavirus and, if they do, getting a more benign version of the illness, Prof Chung says that a young person with an underlying health condition isn't at a greater risk: A young person with asthma, or heart disease, wouldnt be predisposed to get the coronavirusor suffer from it, in the same way an adult with the condition would, he says. Maybe its their immune system, and how its different from older people, but in terms of their susceptibility of getting the coronavirus, health conditions in young people dont seem to increase their chances of catching it.

More:
Coronavirus: how diabetes, asthma and other underlying health conditions affect how you cope - The Telegraph

Hygieia has introduced its d-Nav insulin management program that determines how much insulin a patient needs at the time of injection. // Stock photo

Hygieia, a medical technology company in Livonia, on Thursday introduced its FDA cleared d-Nav insulin management program that automatically determines how much insulin a patient needs at the time of injection.

Using artificial intelligence and patented technology, Hygieias d-Nav system allows patients to get the recommended dose of insulin when they need it, which helps them better manage their glucose levels. The new offering upends the standard of insulin management for people with Type 2 diabetes.

Its a dramatic change from todays standard of care in which a patients insulin dose is modified only when he or she can see a physician for evaluation every few months, the company says. That creates a barrier to care, because peoples insulin needs are dynamic and often require much more frequent titration.

Nearly 70 percent of people using insulin to manage their blood sugar levels fail to achieve recommended A1c levels, says Eran Bashan, CEO of Hygieia. We developed a way to make insulin therapy safe and effective through a technology that doesnt add burden to an already resource-challenged health system.

The d-Nav program uses a handheld device and patented technology to measure glucose, identify glucose patterns, and automatically calculate the next individualized insulin dose. Users simply insert their test strip into a handheld device and d-Nav analyzes the information and provides a recommended insulin dose. For many users, the dose changes every few days.

Through titration, the company says d-Nav offers a safe and effective therapy for managing blood glucose levels. Studies have shown that within three months of starting d-Nav, 90 percent of users lowered their HbA1c levels.

Additionally, when insulin is working more effectively, there is an opportunity to move people to less expensive insulin and to reconsider the need for additional, more costly medications. In fact, a health economic study showed*that people using d-Nav translated into cost savings of approximately $500 per patient, per month.

When physicians first started prescribing insulin some 100 years ago, it was a medical breakthrough and a life-saving medication for insulin-requiring patients, says Bashan. Decades later, the growing number of patients makes it hard to sustain that standard. Hygieias d-Nav program serves as a collaborative insulin specialist helping patients safely and effectively manage their blood sugar levels.

The system is designed to enable physicians, both primary care and endocrinologists, the ability to extend their continuous, personalized care to insulin treated patients with Type 2 diabetes without overtaxing office time and resources.

Patients on the d-Nav program receive test strips, lancets, a glucose monitor pre-loaded with the d-Nav app, and unlimited remote monitoring and clinical support. Physicians who prescribe d-Nav receive data and reports on their patients status, helping them with ongoing blood sugar management.

For more information, contactHygieia.com.

* Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses,Journal of Health Economics and Outcomes Research, JHEOR 2018;6(1):53-62

Continued here:
Hygieia Releases System That Determines How Much Insulin Type 2 Diabetes Patients Need at Time of Injection - dbusiness.com

MedicalResearch.com Interview with:

Gian Paolo Fadini, MD PhDAssociate Professor of EndocrinologyDepartment of Medicine, University of PadovaVenetian Institute of Molecular Medicine

MedicalResearch.com: What is the background for this study?

Response: Since the very beginning of the SARS-CoV-2 pandemic, it was suggested thatIt has been initially suggested that diabetes mellitus is one of the most common comorbidities in infected people, but its exact prevalence is unclear.

However, exact numbers were uncertain. We have addressed this issue in a study published as a letter in the Journal of Endocrinological Investigation.

MedicalResearch.com: What are the main findings?

Response: According to 12 studies reporting data from 2108 Chinese patients and preliminary data from Italian patients with SARS-CoV-2 infection, diabetes does not increase the risk of new coronavirus infection.

However, diabetes could worsen the outcome of this new coronavirus disease, increasing the risk of intensive care unit admission and death.

MedicalResearch.com: What should readers take away from your report?

Response: Diabetic patients should be reassured that they are not at increased risk of getting infected by new coronavirus. Yet, they still need to follow strictly the health recommendations, including wearing personal protection devices and maintain social distancing. Particular attention should be payed to alarm symptoms in diabetic patients, because diabetes could accelerate disease course.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Our data are only preliminary and need to be confirmed in more studies from more countries in the world. We are actively collecting data to evaluate the prevalence and impact of diabetes on COVID-19 and were are exploring is some diabetes therapies can be more effective than others in preventing the infection and / or disease progression.

MedicalResearch.com: Is there anything else you would like to add?

Response: Close monitoring of these data are important for a correct communication to patients and healthcare providers. However, caution should be payed when interpreting data on COVID-19 because the situation is highly dynamic and solid data will be available most likely when the pandemic has finished.

Citation:

Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2 [published online ahead of print, 2020 Mar 28].J Endocrinol Invest. 2020;10.1007/s40618-020-01236-2. doi:10.1007/s40618-020-01236-2

https://pubmed.ncbi.nlm.nih.gov/32222956/

We respect your privacy and will never share your details.

Apr 10, 2020 @ 7:11 pm

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

0

Original post:
Diabetes Could Increase Severity of COVID-19, Including Risk of ICU Admission and Death - MedicalResearch.com

Blood glucose meters and testing strips are an important part of treating diabetes.Photograph: vitapix/Getty

Together with cardiovascular diseases, cancers and chronic respiratory diseases, diabetes has become one of the worlds four major non-communicable diseases (NCDs), and one of the only chronic diseases that continues to increase in prevalence.

According to the World Health Organization (WHO), the number of people with diabetes increased from 108 million in 1980 to 422 million in 2014, and in 2016 it caused 1.6 million deaths, making it the seventh leading cause of death. The WHO estimates deaths from diabetes will increase to 2.4 million in 2030 and 3.7 million in 2045.

Diabetes is a disease in which the body is unable to regulate blood sugar. Patients with type 1 diabetes cant produce insulin in the pancreas due to an auto-immune disease, while those with type 2, once called adult-onset as it often develops in later life no longer produce insulin because of issues such as excessive body weight and insufficient exercise. Its estimated that type 2 diabetes accounts for 90-95% of cases worldwide.

The pharmaceutical industry is ramping up efforts to tackle diabetes through Global Health Progress, with more than 40 partnerships now researching new medicines, as well as new ways in which to diagnose and raise awareness of the disease.

But whats important, says Vanessa Peberdy, head of NCD advocacy and policy at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), is that the dialogue around diabetes treatment and care is not just confined to discussions on affordability and access to insulin. While this is clearly a critical issue, improving treatment and care requires a holistic approach that recognises the complexity of the condition. It needs to take in issues such as a lack of trained health practitioners, inadequate supply chains and weak health systems in developing countries.

Access is a complex issue, says Helen McGuire, programme leader, noncommunicable diseases at global health organisation Path. Failures of access in low-resource settings are rarely due to a single cause.

Barriers must be addressed by leveraging multi-sectoral partnerships, which bring the unique expertise and resources of governments, non-profits, and industry to the table. Solutions require a long-term approach addressing issues of quality, affordability, availability, acceptability, and sustainability.

Emma Klatman is a health systems specialist at the international diabetes charity Life for a Child, which is tackling type 1 diabetes in low and middle income countries, where mortality rates among young people are especially high.

Living without treatment can have horrific consequences, she says, and young people are faced with blindness, losing limbs, developing kidney problems, and they just remain chronically unwell. They can struggle to complete their education, and find employment and marriage partners, and really do face a lot of social stigma.

The charity supplies local health centres with insulin, as well as blood glucose meters and testing strips, which Klatman says are an equally important part of effectively treating diabetes.

Its a point echoed by McGuire. Self-care is essential to meet the daily demands of managing diabetes therefore it is critical to take a people-centered approach to designing solutions, she says. Co-packaging of insulin, syringes, and glucose monitoring devices and strips together at an affordable price would go a long way to support people living with diabetes to safely administer insulin and monitor their glucose levels in low- and middle-income countries.

Next year is the centenary of insulins discovery, and ever since its first use the pharmaceutical industry has been developing new ways in which it can be delivered to patients.

The first insulin pen was introduced in 1985 and immediately improved the accuracy of treatment. Now researchers are exploring an oral treatment for type 2 diabetes that will mean patients no longer need to inject at all. A smart insulin patch is also being developed that delivers tailored amounts of insulin into the bloodstream, and a new generation of insulin pumps can now be connected wirelessly to a blood glucose meter or under-the-skin sensor to monitor and regulate insulin.

Research into the development of an artificial pancreas at the University of Cambridge is on-going, as is R&D into cell therapy, when living cells are injected into patients to take over the function of the faulty ones.

Sanofi, which along with Novo Nordisk and Eli Lilly make up the big three insulin manufacturers, has recently changed its approach to diabetes, shifting emphasis from new treatments to helping people to use existing medicines more effectively.

Working with Biocorp, for instance, Sanofi is developing a new connected pen that automatically records dosage information through a mobile app. Its MyStar DoseCoach blood glucose meter uses a dose adjustment (titration) scheme to recommend daily doses of long-acting insulin, based on daily blood sugar measurements linked to any incidents of low blood sugar through the day.

Looking at the economics of diabetes, Novo Nordisks Base of the Pyramid programme in Kenya addresses the many barriers to diabetes care faced by people on low incomes. It takes on board issues such as poverty, geography and gender, as well as the limitations of national health systems. Cost of transport, having to miss a days work and the need to buy equipment such as syringes are also flagged up.

Through working in partnerships across the supply chain, one of its successes has been a 75% reduction in the price of insulin. But, explains Soraya Ramoul, Novo Nordisks director of global access to care, the programme also showed that the price reduction in itself does not provide people with access to good care. Diabetes is a complex condition, which requires a systemic approach to ensure basic quality care and management, she says.

Affordability of insulin is just one of the necessary components, along with creating awareness in the communities, building capacity for care and medicine supply, educating patients, improving demand forecasting and reducing transportation costs for the patients.

Klatman sees the growth of partnerships like this as crucial to providing the level of diabetes care that is needed in developing countries, and looks forward to the day when families are able to access insulin and other supplies without being exposed to financial risk, and having to make really tough decisions to keep their kids alive.

Link:
Global health policy: can we manage the ever-increasing rise of diabetes? - The Guardian

Type 2 Diabetes- Pipeline Intelligence, 2019 MarketLatest Research Report 2020:

The Type 2 Diabetes- Pipeline Intelligence, 2019 report provides an independent information about the Type 2 Diabetes- Pipeline Intelligence, 2019 industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Type 2 Diabetes- Pipeline Intelligence, 2019 Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Type 2 Diabetes- Pipeline Intelligence, 2019 Market: Products in the Type 2 Diabetes- Pipeline Intelligence, 2019 classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Company I, Company II, Company III, Company IV and more

Type 2 Diabetes- Pipeline Intelligence, 2019 Market Report Covers the Following Segments:

Segment by Type:Type I, Type II, Type III

Segment by Application:Application I, Application II, Application III

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Type 2 Diabetes- Pipeline Intelligence, 2019 Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Type 2 Diabetes- Pipeline Intelligence, 2019 Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Type 2 Diabetes- Pipeline Intelligence, 2019 Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Type 2 Diabetes- Pipeline Intelligence, 2019 Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Type 2 Diabetes- Pipeline Intelligence, 2019 Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Type 2 Diabetes- Pipeline Intelligence, 2019 Market.

Market Forecast:Here, the report offers a complete forecast of the global Type 2 Diabetes- Pipeline Intelligence, 2019 Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Trending Reports:

https://brandessenceresearch.com/technology-and-media/ip-camera-market-latest

https://brandessenceresearch.com/chemical-and-materials/sodium-acetate-market-size-and-share

https://brandessenceresearch.com/technology-media/cloud-gaming-market

https://www.marketwatch.com/press-release/europe-printing-inks-market-2020-demand-analytics-top-companies-types-application-growth-drivers-size-share-and-industry-analysis-forecast-2025-2020-04-10

Original post:
Coronavirus Outbreak: Type 2 Diabetes Market Size : Industry Growth, Competitive Analysis, Future Prospects and Forecast 2025 - Curious Desk

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2020 results after the financial markets close on Thursday, April 30, 2020. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2020 financial and operating results.

Conference Call/Webcast Details:Date: April 30, 2020Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Toll Free Dial-In Number: (855) 427-4396International Dial-In Number: (484) 756-4261Conference ID: 2116108Webcast Link: https://edge.media-server.com/mmc/p/a3oa6ode

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Cares Investor Center website located at http://investor.tandemdiabetes.com in the Events & Presentations section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandems flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring, and optional automated insulin delivery technology. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and $TNDM.Follow Tandem Diabetes Care on Facebook at http://www.facebook.com/TandemDiabetes.Follow Tandem Diabetes Care on LinkedIn at http://www.linkedin.com/company/TandemDiabetes.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Link:
Tandem Diabetes Care to Announce First Quarter 2020 Financial Results on April 30, 2020 - Business Wire

Those with pre-existing illnesses such as diabetes ought to be more concerned about the coronavirus outbreak here, metabolic disease expert Yusuf Ali told The Straits Times on Thursday.

Senior Parliamentary Secretary for Health Amrin Amin had said in Parliament in February that each year, an estimated 19,000 people in Singapore are diagnosed with Type 1 or Type 2 diabetes.

Assistant Professor Yusuf, from the Lee Kong Chian School of Medicine at Nanyang Technological University, said people with such conditions have a weakened ability to protect themselves from the virus.

"The long-elevated blood glucose in diabetes weakens the immune response. This will affect the natural ability of the body to fight against the virus, making the management of the condition harder," he said.

Citing a recent study on cases of Covid-19 infection in China, he noted that among those who were infected with the disease, the death rate for diabetics was 7.3 per cent, compared with 2.3 per cent overall.

In Singapore, at least two of those who died from the virus had a history of diabetes.

Prof Yusuf said that as there is currently no treatment or vaccine for Covid-19, the disease is managed by alleviating symptoms and ensuring that one's body has the right nourishment to mount a good defence against it.

For the time being, he said, diabetics should spend time doing simple exercises at home, and maintain a high standard of hygiene by washing their hands with soap and water regularly, not touching their faces, and staying away from people who are coughing.

Those on medication should ensure that they have enough to last them for two to four weeks.

Finally, they need to manage their blood glucose levels well.

"Poor glycaemic control not only makes management of viral infections harder, but also lowers your immune bar, thus increasing the risk of such infections," he said.

Timothy Goh

Follow this link:
Diabetes weakens body's ability to fight coronavirus, Health News & Top Stories - The Straits Times